RE: Interesting development9 Feb 2024 14:00
That might not be Stalicla's CEO's style but the recent funding included new BOD's which I suspect are more profit driven...
Why pay all this money when we can starve Evgen of cash, maybe make a hostile takeover...
'Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double-digit range in all scenarios, including on-licensing by Stalicla and use of SFX-01 in further licensed indications'
The Cancer treatment could be farmed out and Stalicla could save themselves a few hundred million $$ just buy taking over Evgen...
Wild speculation but that's what I'd be thinking if SFX-01 looks like it will work